MIR — Mirion Technologies, Inc.

Summary of Mirion Technologies Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue reached $223 million, an increase of 7.9% year-over-year, with organic growth of 4.7%.
• Adjusted EBITDA: Increased by 14.7% to $52.4 million, reflecting margin expansion across segments.
• Adjusted Free Cash Flow: Totaled $18 million for the quarter, contributing to $53 million year-to-date, with a conversion rate of 35% of adjusted EBITDA.
• Adjusted EPS: Rose 50% to $0.12 per share; if adjusted for share count, it would have been $0.15.
• Debt: Year-end expected blended cost of debt is projected at 2.8%, a significant reduction from the previous year.

2. Strategic Updates and Business Highlights

• Nuclear Power Market: The nuclear power segment is a key driver, with organic revenue growth of 9% in Q3 and 11% year-to-date. Mirion expects to benefit from the ongoing nuclear renaissance.
• Acquisitions: The acquisition of Paragon Energy Solutions is expected to close by year-end, enhancing Mirion’s portfolio in the nuclear power sector.
• Medical Segment: The medical division saw organic revenue growth of 5.2%, driven by dosimetry services. However, the RTQA business faces challenges due to pressures in the U.S. healthcare environment.

3. Forward Guidance and Outlook

• Adjusted Free Cash Flow Guidance: Increased to a range of $100 million to $115 million for 2025, with a conversion rate of 45% to 49% of adjusted EBITDA.
• Nuclear Power Orders: Anticipated strong order growth in Q4, particularly in the nuclear power segment, with a focus on small modular reactors (SMRs).
• Long-term Outlook: Mirion remains optimistic about the nuclear power market, citing government support and increasing capacity factors.

4. Bad News, Challenges, or Points of Concern

• U.S. Healthcare Environment: The RTQA business is under pressure, with delays in customer activity attributed to government funding issues and potential impacts from a government shutdown.
• Order Flow from Labs and Research: Demand from the U.S. Department of Energy has been muted, and order flow from China for laboratory instruments has slowed, though this is viewed as transitory.
• Market Uncertainty: The timing of new nuclear projects remains unpredictable, and while there is optimism about future orders, the company is cautious about projecting exact timelines.

5. Notable Q&A Insights

• Nuclear Power Backlog: Management expressed confidence in the potential for backlog growth, driven by the installed base and new utility-scale builds, although timing remains uncertain.
• Medical Business Outlook: Despite current pressures, management remains positive about the long-term growth potential of the medical segment, driven by demographic trends and increasing cancer treatment needs.
• SMR Opportunities: The company has booked $26 million in SMR orders year-to-date, with expectations for continued growth in this area, supported by recent government funding initiatives.
• Pricing Power: Mirion has maintained positive pricing dynamics, particularly in the nuclear safety segment, although pricing strategies in the medical segment are more conservative due to current market conditions.

Overall, Mirion Technologies reported solid Q3 results, driven by the nuclear power segment, while facing challenges in the medical business. The company is strategically positioned for future growth through acquisitions and strong market demand, although uncertainties in the healthcare environment and project timelines remain concerns.